FILANA THERAPEUTICS, INC. (FLNA)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

0 15M 30M 45M Q1 '10: 3.2M Q2 '10: 2.7M Q3 '10: 2.9M Q4 '10: 8M Q1 '11: 3.2M Q2 '11: 2.8M Q3 '11: 2.7M Q4 '11: 2.7M Q1 '12: 3M Q2 '12: 2.7M Q3 '12: 2.7M Q4 '12: 2.5M Q1 '13: 2M Q2 '13: 2M Q3 '13: 2M Q4 '13: 35.2M Q2 '10 Q4 '10 Q2 '11 Q4 '11 Q2 '12 Q4 '12 Q2 '13 Q4 '13

Gross Profit Quarterly

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income Quarterly

-75M -50M -25M 0 25M 50M 75M Q2 '21: -5.1M Q3 '21: -9.8M Q4 '21: -14.4M Q1 '22: -17.8M Q2 '22: -19.9M Q3 '22: -21.3M Q4 '22: -20.9M Q1 '23: -26.5M Q2 '23: -28.8M Q3 '23: -27.9M Q4 '23: -22.8M Q1 '24: -19.9M Q2 '24: -61.4M Q3 '24: -30.6M Q4 '24: -29.5M Q1 '25: -24.6M Q2 '25: -45.4M Q3 '25: -11.9M Q4 '25: -13.6M Q1 '26: -11.2M Q3 '21 Q2 '22 Q1 '23 Q4 '23 Q3 '24 Q2 '25 Q1 '26

Net Income Quarterly

-60M -40M -20M 0 20M 40M 60M Q2 '21: -5.1M Q3 '21: -9.6M Q4 '21: -14.2M Q1 '22: -17.5M Q2 '22: -19.3M Q3 '22: -20.3M Q4 '22: -19.1M Q1 '23: -24.3M Q2 '23: -26.4M Q3 '23: -25.7M Q4 '23: -20.9M Q1 '24: 25M Q2 '24: 6.2M Q3 '24: -27.9M Q4 '24: -27.6M Q1 '25: -23.4M Q2 '25: -44.2M Q3 '25: -10.8M Q4 '25: -12.5M Q1 '26: -10.3M Q3 '21 Q2 '22 Q1 '23 Q4 '23 Q3 '24 Q2 '25 Q1 '26

Cost of Revenue Quarterly

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow Quarterly

-75M -50M -25M 0 25M 50M 75M Q2 '21: -5.1M Q3 '21: -14.8M Q4 '21: -8M Q1 '22: -23.5M Q2 '22: -11.1M Q3 '22: -21.6M Q4 '22: -21.3M Q1 '23: -13.3M Q2 '23: -19.9M Q3 '23: -26.5M Q4 '23: -22.3M Q1 '24: -19.1M Q2 '24: -18.2M Q3 '24: -18.3M Q4 '24: -61.3M Q1 '25: -11.3M Q2 '25: -4.9M Q3 '25: -6.2M Q4 '25: -9.7M Q1 '26: -8.9M Q3 '21 Q2 '22 Q1 '23 Q4 '23 Q3 '24 Q2 '25 Q1 '26

Free Cash Flow Quarterly

-75M -50M -25M 0 25M 50M 75M Q2 '19: -591K Q3 '19: -730K Q4 '19: -589K Q3 '21: -36.8M Q4 '21: -8.1M Q1 '22: -24M Q2 '22: -12.6M Q3 '22: -22.7M Q1 '23: -13.6M Q2 '23: -19.9M Q3 '23: -26.6M Q4 '23: -22.4M Q1 '24: -19.1M Q2 '24: -18.3M Q3 '24: -18.3M Q4 '24: -61.3M Q1 '25: -11.3M Q2 '25: -4.9M Q3 '25: -6.3M Q4 '25: -10.2M Q3 '19 Q4 '21 Q3 '22 Q3 '23 Q2 '24 Q1 '25 Q4 '25

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 20M 40M 60M Q1 '11: 43.1M Q1 '12: 44.8M Q1 '13: 44.9M Q1 '22: 40M Q2 '22: 40M Q3 '22: 40M Q1 '23: 41.7M Q2 '23: 41.8M Q3 '23: 42M Q1 '24: 44.1M Q2 '24: 46.2M Q3 '24: 48M Q1 '25: 48.3M Q2 '25: 48.3M Q3 '25: 48.3M Q1 '11 Q1 '13 Q2 '22 Q1 '23 Q3 '23 Q2 '24 Q1 '25 Q3 '25

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-2.70 -1.80 -0.90 0.00 0.90 1.80 2.70 Q2 '21: -0.37 Q3 '21: -0.55 Q4 '21: -0.82 Q1 '22: -1.17 Q2 '22: -1.52 Q3 '22: -1.79 Q4 '22: -1.90 Q1 '23: -2.04 Q2 '23: -2.19 Q3 '23: -2.29 Q4 '23: -2.32 Q1 '24: -2.17 Q2 '24: -1.41 Q3 '24: -1.38 Q4 '24: -1.46 Q1 '25: -1.51 Q2 '25: -2.56 Q3 '25: -2.20 Q4 '25: -1.88 Q1 '26: -1.61 Q3 '21 Q2 '22 Q1 '23 Q4 '23 Q3 '24 Q2 '25 Q1 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.